Idelalisib (GS-1101)-Associated Colitis - Molecular and Cellular Mechanisms Research Proposal
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- 11 Oct 2017 Planned primary completion date changed from 1 Dec 2028 to 1 Feb 2028.
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.
- 14 Oct 2016 New trial record